Salt Lake City, UT – May 15, 2019 – DiscGenics, Inc. congratulates Chief Medical Officer, Kevin T. Foley, MD, FACS, FAANS on being awarded the 2019 AANS Cushing Award for Technical Excellence and Innovation in Neurosurgery. The award was presented at the 87th American Association of Neurological Surgeons (AANS) Annual Scientific Meeting, held April 13 – 17, 2019 in San Diego.
The Cushing Award honors an AANS member for technical prowess and skill and/or innovation in the development of new procedures that have become part of the arsenal a neurosurgeon uses to treat disease or trauma.
Dr. Foley is a founding member of DiscGenics and serves as the Company’s Chief Medical Officer and on its Board of Directors. He is also a practicing neurosurgeon and active entrepreneur who invented many of the surgical devices and techniques (tubular retractors, percutaneous pedicle screws with removable extenders) that have revolutionized minimally invasive spine surgery. Dr. Foley is the Chairman of Semmes-Murphy Neurologic & Spine Institute and a tenured professor of neurosurgery, orthopedic surgery and biomedical engineering at the University of Tennessee. He has authored over 35 book chapters and more than 125 journal publications, lectured at more than 600 scientific meetings and educational workshops, and holds more than 150 patents issued by the USPTO. Dr. Foley received his M.D. from UCLA.
About DiscGenics
DiscGenics is a privately held, clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. As the only company in the world to develop an allogeneic cell therapy derived from intervertebral disc cells to treat diseases of the disc, DiscGenics believes it has a unique opportunity to harness the restorative potential of the human body to heal millions of patients suffering from the debilitating effects of back pain. DiscGenics’ first product candidate, an injectable disc cell therapy, or IDCT, is a homologous, allogeneic, injectable cell therapy that utilizes proprietary Discogenic Cells to offer a non-surgical, potentially regenerative solution for the treatment of patients with mild to moderate degenerative disc disease.